Citius Pharmaceuticals (CTXR) risk factors
Item 1A of every Citius Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks2 new2 dropped18 reworded
The risk profile centers on the commercial launch and market uptake of LYMPHIR for CTCL following its December 2025 rollout. Financial constraints, dependence on partner Citius Oncology, and Nasdaq listing compliance remain critical threats.
Filed Dec 23, 2025 - FY2024 10-K risk factors53 risks
Citius Pharmaceuticals faces going concern doubts and requires immediate funding to support operations and launch LYMPHIR. The company relies heavily on third parties for manufacturing, clinical trials, and commercialization of its product candidates. Future profitability depends entirely on regulatory approvals and market acceptance of unproven pipeline assets like LYMPHIR and Mino-Lok.
Filed Dec 27, 2024